Finance

Beta
Lists
RCKT:NASDAQ
Rocket Pharmaceuticals Inc
$3.96
+3.26%
(+0.12) 1D
Jul 6, 10:43:05 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RCKT...
Open
$3.82
High
$4.00
Low
$3.82
Mkt. cap
432.95M
Avg. vol.
2.90M
Volume
381.36K
52-wk high
$5.45
52-wk low
$2.53
EPS
-$1.88
Beta
0.45
Shares outstanding
109.19M
No. of employees
202
Open
$3.82
High
$4.00
Low
$3.82
Mkt. cap
432.95M
Avg. vol.
2.90M
Volume
381.36K
52-wk high
$5.45
52-wk low
$2.53
EPS
-$1.88
Beta
0.45
Shares outstanding
109.19M
No. of employees
202
News stories
From sources across the web
About Rocket Pharmaceuticals Inc
CEO-
Employees202
Founded1999
HeadquartersCranbury, New Jersey, United States
SectorBiotechnology
Websiterocketpharma.com
Analyst ratings
Based on 7 analysts giving stock ratings to RCKT in the past 3 months
Buy
Buy
5
Hold
2
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for RCKT in the last 3 months.
Highest
Current $3.96
$16.00 (+303.53%)
Average
$11.80 (+197.60%)
Lowest
$10.00 (+152.21%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Zemansky
Bank of America Securities
Buy
Maintained
$10.00
+152.2%
06/11/2026
Tara Bancroft
TD Cowen
Hold
Maintained
-
-
05/10/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$11.00
+177.4%
05/10/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$10.00
+152.2%
05/07/2026
Patrick Dolezal
LifeSci Capital
Buy
Reiterated
$12.00
+202.6%
05/09/2026
Yun Zhong
Wedbush
Buy
Reiterated
$16.00
+303.5%
05/08/2026
Gil Blum
Needham
Hold
Maintained
-
-
05/08/2026
Tessa Romero
J.P. Morgan
Sell
Maintained
-
-
04/02/2026
Mani Foroohar
Leerink Partners
Hold
Reiterated
$11.00
+177.4%
03/27/2026
Richard Law CFA
Goldman Sachs
Sell
Maintained
$3.00
-24.3%
03/27/2026
Michael Ulz
Morgan Stanley
Hold
Maintained
$5.00
+26.1%
03/27/2026
Unknown Analyst
Canaccord Genuity
Buy
Maintained
$10.00
+152.2%
03/02/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$10.00
+152.2%
02/27/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
02/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
42.66M
34.07M
29.35M
31.45M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
25.02M
18.35M
14.68M
17.06M
Operating expense
67.68M
52.42M
44.03M
48.51M
Total operating expenses
67.68M
52.42M
44.03M
48.51M
Operating income
-67.68M
-52.42M
-44.03M
-48.51M
Other non operating income
-
-
-
-
EBT including unusual items
-68.92M
-50.33M
-42.54M
-47.59M
EBT excluding unusual items
-67.67M
-52.18M
-43.81M
-48.82M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-68.92M
-50.33M
-42.54M
-47.59M
Net profit margin
-
-
-
-
Earnings per share
-0.59
-0.45
-0.38
-0.42
Interest and investment income
483.00K
709.00K
690.00K
161.00K
Interest expense
-473.00K
-473.00K
-473.00K
-473.00K
Net interest expenses
10.00K
236.00K
217.00K
-312.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-65.10M
-49.18M
-41.81M
-46.36M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer